Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.37 |
| ▸ | SYK | P43405 | 5/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 3/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | SPR | P35270 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23976402 | 1.00 | HDAC1 (0.37) | HDAC1HDAC8HDAC6SYKPDE2A | |
| SCHEMBL30118688 | 0.89 | HDAC1 (0.33) | HDAC1HDAC8HDAC6PIK3C3ACHE | |
| SCHEMBL23976937 | 0.89 | HDAC1 (0.33) | HDAC1HDAC8HDAC6PIK3C3ACHE | |
| SCHEMBL30118604 | 0.88 | SYK (0.36) | HDAC1HDAC8HDAC6SYKPDE10A | |
| SCHEMBL23975999 | 0.88 | SYK (0.36) | HDAC1HDAC8HDAC6SYKPDE10A | |
| SCHEMBL23976709 | 0.88 | SYK (0.36) | HDAC1HDAC8HDAC6SYKPDE10A | |
| SCHEMBL23986789 | 0.88 | SYK (0.39) | HDAC1HDAC8HDAC6SYKPDE10A | |
| SCHEMBL30118742 | 0.87 | SYK (0.39) | HDAC1HDAC8HDAC6SYKACHE | |
| SCHEMBL23975673 | 0.87 | SYK (0.39) | HDAC1HDAC8HDAC6SYKACHE | |
| SCHEMBL23975777 | 0.85 | SYK (0.38) | HDAC1HDAC8HDAC6SYKPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| EP-4143178-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4142732-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | HDAC1 4619/4885HDAC8 4526/4885HDAC6 4500/4885 |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | HDAC1 4175/4885HDAC8 4257/4885HDAC6 4235/4885 |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | HDAC1 4175/4885HDAC8 4257/4885HDAC6 4235/4885 |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | HDAC1 4175/4885HDAC8 4257/4885HDAC6 4235/4885 |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | HDAC1 4175/4885HDAC8 4257/4885HDAC6 4235/4885 |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | HDAC1 4175/4885HDAC8 4257/4885HDAC6 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.